Richard Ghalie, MD

Trials

Studies that name Richard Ghalie, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:56 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT03547115 · A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

  MEI Pharma, Inc. · terminated · Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) · study director
• Ph2
  NCT03151304 · A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

  Helsinn Healthcare SA · terminated · Myelodysplastic Syndromes · study director
• Ph1/Ph2
  NCT02100007 · ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

  MEI Pharma, Inc. · terminated · Solid Tumors · study director
• Ph2
  NCT01601340 · Effects of HQK-1001 in Patients With Sickle Cell Disease

  HemaQuest Pharmaceuticals Inc. · terminated · Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders · study director
• Ph2
  NCT01322269 · A Study of HQK-1001 in Patients With Sickle Cell Disease

  HemaQuest Pharmaceuticals Inc. · completed · Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.